Research
Resveratrol fact-checked: what the evidence supports
Between what resveratrol shows in the laboratory and what studies in humans measure, there is a wide gap.
Resveratrol has raised high expectations for years. It is called a “longevity molecule”, a SIRT1 activator, or a protector of the heart, metabolism and brain. Between what resveratrol shows in the laboratory and what studies in humans measure, however, there is a wide gap.1
This article sorts the meta-analyses of randomised trials on markers of inflammation, blood pressure, blood sugar, SIRT1 and the liver. It adds 2 questions that are rarely asked: How much of it reaches the blood, and what does EU law allow?
What is resveratrol, and where is it found?
Resveratrol is a polyphenol from the stilbene group. It should not be confused with the flavonoids, which include quercetin, for example. Plants produce it to fend off fungi and bacteria. It has been detected in more than 70 plant species, especially in grape skins and seeds, and in small amounts in red wine. In 1963 it was isolated from the roots of Japanese knotweed.1

Resveratrol exists in 2 forms: cis and trans. The trans form predominates, is more stable and is considered biologically more active.1 In the EU it is authorised as a novel food under the name “trans-resveratrol”.2 Grape seeds, by the way, also yield a quite different extract: OPC.
How much resveratrol reaches the body?
This is the biggest hurdle. In humans, the gut absorbs about 75% of a swallowed amount. The gut and liver convert it so quickly, however, that less than 1% reaches the bloodstream unchanged. What circulates there is mainly glucuronide and sulphate compounds. Higher or repeated amounts change this little.3
Well absorbed, barely unchanged in the blood
Share of a swallowed amount of resveratrol in humans
A study in 40 healthy volunteers shows the ratio. They took 0.5 to 5 g daily for 29 days. Afterwards, the breakdown products in the blood were up to 20.3 times higher than unchanged resveratrol.4
Red wine does not change this. After moderate red wine consumption, researchers found free trans-resveratrol in 25 healthy people only in traces, only in some samples and only after 30 minutes. After that, the glucuronides predominated, with or without a meal.5
More milligrams therefore do not automatically mean more unchanged resveratrol in the blood. Whether tissues split the compounds back into resveratrol is under discussion.3
Why is research so interested in resveratrol?
The list of laboratory findings is long: antioxidant, anti-inflammatory, vasorelaxant, neuroprotective and more.1 Research attributes many of these properties to SIRT1, an enzyme from the sirtuin family.6
This is exactly where the misunderstanding begins. An effect in cell culture or in an animal model is a hypothesis, not a finding in humans. That is why what follows counts randomised trials in humans and their meta-analyses.

What do studies show on markers of inflammation and blood pressure?
A meta-analysis of 6 randomised trials in people with cardiovascular disease found lower values for CRP and TNF-α, 2 markers of inflammation. For IL-6 there was no difference.7 A larger analysis of 40 trials with 2,551 participants with metabolic disorders found lower values for all 3 markers.8
For blood pressure the picture is mixed. Across 17 trials there was no established difference. Systolic pressure was lower only in subgroups: at amounts of 300 mg daily or more and in people with diabetes.9 This fits a meta-analysis of 5 trials with 388 people with type 2 diabetes on glucose-lowering medication. Systolic blood pressure was lower, while creatinine and urea as kidney values remained unchanged.10 The 2026 analysis also found lower blood pressure values.8
Inflammation markers and blood pressure: isolated signals
Meta-analyses of randomised trials, resveratrol compared with the control group
Teimouri 2022 · 6 trials, cardiovascular disease
Fogacci 2018 · 17 trials
Shen 2026 · 40 trials, 2,551 participants with metabolic disorders
The pattern is typical: individual measurements shift, often only in subgroups. None of these meta-analyses assessed hard endpoints such as heart attack or mortality.7-10
Does resveratrol help with type 2 diabetes?
The popular story goes like this: resveratrol activates SIRT1, improves sugar metabolism and mimics calorie restriction. In humans, this is poorly supported.
The Cochrane review found only 3 trials with a total of 50 participants. They ran for 4 to 5 weeks with 10 to 1,000 mg daily. HbA1c, fasting blood sugar and insulin resistance did not differ from placebo. No trial examined long-term endpoints that matter to patients. The verdict: the data support neither a benefit nor harm. 8 further trials with about 800 participants were still ongoing at the time.11
A meta-analysis of 30 trials takes a broader view. It found fasting blood sugar 5.24 mg/dl lower and lower insulin values, mainly in type 2 diabetes. HbA1c and HOMA-IR, a measure of insulin resistance, did not change.12
A small difference in a laboratory value is therefore possible, an established effect in diabetes is not. Anyone who derives a treatment from this goes beyond the data.
Does resveratrol activate SIRT1 in humans?
Hardly any mechanism has shaped resveratrol's reputation as much as SIRT1. A 2025 meta-analysis assessed 11 randomised trials on this and rated the certainty of the findings with the GRADE system.6
The result: no difference in SIRT1, neither in gene expression (4 trials) nor in protein (5 trials) nor in blood levels (3 trials). Gene expression was higher in only one subgroup: trials under 12 weeks, measured in blood. The dose-response analysis suggests that the dosing regimen plays a role.6
The statement “resveratrol reliably activates SIRT1 in humans” is therefore not tenable. That is not a step backwards: good research weeds out exaggerations.
What do studies show on fatty liver and liver values?
In non-alcoholic fatty liver disease (NAFLD) the mechanisms sound convincing. The studies in humans do not.
A meta-analysis of 7 trials with 302 patients found no difference in the parameters studied. The trials ran for 56 to 180 days with 500 to 3,000 mg daily. The only exception: ALT, a liver enzyme, rose with resveratrol.13 Across 15 trials with 714 participants, ALT, AST, GGT, alkaline phosphatase and bilirubin remained unchanged.14 The 2026 analysis also found no consistent change in liver values or liver fat.8
Sugar, SIRT1, liver: mostly no difference
Meta-analyses of randomised trials, resveratrol compared with the control group
Cochrane 2020 · 3 trials, 50 people with type 2 diabetes, 4-5 weeks
García-Martínez 2021 · 30 trials
Mansouri 2025 · 11 trials
Jakubczyk 2020 · 7 trials, 302 people with fatty liver
Darand 2020 · 15 trials, 714 participants
What amounts were studied, and how well were they tolerated?
Study amounts vary widely: 10 to 1,000 mg daily in the diabetes trials, 500 to 3,000 mg in fatty liver.11,13 For blood pressure, a difference appeared only in the subgroup taking 300 mg daily or more.9
On tolerability: in the study with 40 healthy people, resveratrol was considered safe over 29 days. From 2.5 g daily, however, mild to moderate gastrointestinal symptoms occurred.4 Reviews list nausea, vomiting, diarrhoea and impaired liver function from 2.5 g daily.1
EU maximum and study amounts compared
trans-Resveratrol in milligrams per day
Is resveratrol authorised in the EU, and how much is allowed?
In the EU, trans-resveratrol is a novel food. The European Commission authorised it in 2016. The basis was an EFSA opinion: under the proposed conditions, it is safe in food supplements for adults.2,15
The authorisation sets tight limits: only in food supplements, only for adults, only as tablets or capsules and at most 150 mg per day. The label carries the name “trans-resveratrol”.2
Interactions with certain medicines are possible. The EU therefore requires a statement on the label: the product should be consumed only under medical supervision when taking medicines.2
Authorisation as a novel food is not a health claim. It governs safety, amount and labelling, not the effect.2 How to recognise verified claims is explained in the article on EU health claims.
What does this mean overall?
Resveratrol is neither worthless nor a miracle molecule. It is a well-studied plant compound with many laboratory findings. The evidence in humans differs greatly depending on the question.
3 points are solid. Very little reaches the blood unchanged. Individual measurements such as CRP shift in some analyses. For SIRT1, fatty liver and long-term blood sugar, the meta-analyses show no difference.
The most honest summary is therefore not “resveratrol can do everything”, but: resveratrol is a biologically interesting compound whose benefit in humans is limited, context-dependent and not yet settled.
Key takeaways
- trans-Resveratrol is the more stable and more common form. Under this name it is authorised as a novel food in the EU.1,2
- About 75% is absorbed, less than 1% reaches the blood unchanged.3
- For CRP and TNF-α, meta-analyses found lower values; for blood pressure, only in subgroups.7,9
- In type 2 diabetes, according to Cochrane, the data support neither a benefit nor harm.11
- For SIRT1 and liver values, meta-analyses found no difference from the control group.6,14
- EU maximum: 150 mg per day, adults only, with a mandatory statement on medicines.2
Sources
- Salehi B et al. Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines, 2018.
- Commission Implementing Decision (EU) 2016/1190 of 19 July 2016 authorising the placing on the market of trans-resveratrol as a novel food ingredient. Official Journal of the European Union, L 196, 2016.
- Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci, 2011.
- Brown VA et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res, 2010.
- Vitaglione P et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res, 2005.
- Mansouri F et al. Impact of Resveratrol Supplementation on Human Sirtuin 1: A Grading of Recommendations Assessment, Development and Evaluation-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. J Acad Nutr Diet, 2025.
- Teimouri M et al. Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med, 2022.
- Shen CY et al. Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases. In Vivo, 2026.
- Fogacci F et al. Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. Crit Rev Food Sci Nutr, 2018.
- Nyambuya TM et al. A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy. Molecules, 2020.
- Jeyaraman MM et al. Resveratrol for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev, 2020.
- García-Martínez BI et al. Hypoglycemic Effect of Resveratrol: A Systematic Review and Meta-Analysis. Antioxidants (Basel), 2021.
- Jakubczyk K et al. Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis. Nutrients, 2020.
- Darand M et al. Effects of resveratrol supplementation on liver enzymes: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract, 2020.
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal, 2016.
ATLAS All-in-One - 35 ingredients, 4 capsules, once a day.
